Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis
Cytoguardin was identified in the conditioned medium of fibroblasts as a tryptophan metabolite, 5-methoxytryptophan (5-MTP). It is synthesized via two enzymatic steps: tryptophan hydroxylase (TPH) and hydroxyindole O-methyltransferase (HIOMT). A truncated HIOMT isoform, HIOMT298, catalyzes 5-MTP syn...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/9/4490 |
id |
doaj-4a4bccc304864245900cec9de05f26c5 |
---|---|
record_format |
Article |
spelling |
doaj-4a4bccc304864245900cec9de05f26c52021-04-26T23:00:27ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01224490449010.3390/ijms22094490Cytoguardin: A Tryptophan Metabolite against Cancer Growth and MetastasisKenneth K. Wu0Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan Town 35053, TaiwanCytoguardin was identified in the conditioned medium of fibroblasts as a tryptophan metabolite, 5-methoxytryptophan (5-MTP). It is synthesized via two enzymatic steps: tryptophan hydroxylase (TPH) and hydroxyindole O-methyltransferase (HIOMT). A truncated HIOMT isoform, HIOMT298, catalyzes 5-MTP synthesis. Cancer cells produce scarce 5-MTP due to defective HIOMT298 expression. 5-MTP inhibits cancer cell COX-2 expression and thereby reduces COX-2-mediated cell proliferation and migration. 5-MTP also inhibits MMP-9 expression and thereby reduces cancer cell invasion. 5-MTP exerts its anti-cancer effect by blocking p38 MAPK and p38-mediated NF-κB and p300 HAT activation. The stable transfection of A549 cells with HIOMT298 restores 5-MTP production which renders cancer cells less aggressive. The implantation of HIOMT-transfected A549 into subcutaneous tissues of a murine xenograft tumor model shows that HIOMT-transduced A549 cells form smaller tumors and generate fewer metastatic lung nodules than control A549 cells. HIOMT298 transfection suppresses aromatic amino acid decarboxylase (AADC) expression and serotonin production. Serotonin is a cancer-promoting factor. By restoring 5-MTP and suppressing serotonin production, HIOMT298 overexpression converts cancer cells into less malignant phenotypes. The analysis of HIOMT expression in a human cancer tissue array showed reduced HIOMT levels in a majority of colorectal, pancreatic, and breast cancer. HIOMT298 may be a biomarker of human cancer progression. Furthermore, 5-MTP has the potential to be a lead compound in the development of new therapy for the chemoprevention of certain cancers such as hepatocellular cancer.https://www.mdpi.com/1422-0067/22/9/4490cytoguardin5-methoxytryptophancancer growthcancer metastasiscyclooxygenase-2matrix metalloproteinase |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kenneth K. Wu |
spellingShingle |
Kenneth K. Wu Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis International Journal of Molecular Sciences cytoguardin 5-methoxytryptophan cancer growth cancer metastasis cyclooxygenase-2 matrix metalloproteinase |
author_facet |
Kenneth K. Wu |
author_sort |
Kenneth K. Wu |
title |
Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis |
title_short |
Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis |
title_full |
Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis |
title_fullStr |
Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis |
title_full_unstemmed |
Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis |
title_sort |
cytoguardin: a tryptophan metabolite against cancer growth and metastasis |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-04-01 |
description |
Cytoguardin was identified in the conditioned medium of fibroblasts as a tryptophan metabolite, 5-methoxytryptophan (5-MTP). It is synthesized via two enzymatic steps: tryptophan hydroxylase (TPH) and hydroxyindole O-methyltransferase (HIOMT). A truncated HIOMT isoform, HIOMT298, catalyzes 5-MTP synthesis. Cancer cells produce scarce 5-MTP due to defective HIOMT298 expression. 5-MTP inhibits cancer cell COX-2 expression and thereby reduces COX-2-mediated cell proliferation and migration. 5-MTP also inhibits MMP-9 expression and thereby reduces cancer cell invasion. 5-MTP exerts its anti-cancer effect by blocking p38 MAPK and p38-mediated NF-κB and p300 HAT activation. The stable transfection of A549 cells with HIOMT298 restores 5-MTP production which renders cancer cells less aggressive. The implantation of HIOMT-transfected A549 into subcutaneous tissues of a murine xenograft tumor model shows that HIOMT-transduced A549 cells form smaller tumors and generate fewer metastatic lung nodules than control A549 cells. HIOMT298 transfection suppresses aromatic amino acid decarboxylase (AADC) expression and serotonin production. Serotonin is a cancer-promoting factor. By restoring 5-MTP and suppressing serotonin production, HIOMT298 overexpression converts cancer cells into less malignant phenotypes. The analysis of HIOMT expression in a human cancer tissue array showed reduced HIOMT levels in a majority of colorectal, pancreatic, and breast cancer. HIOMT298 may be a biomarker of human cancer progression. Furthermore, 5-MTP has the potential to be a lead compound in the development of new therapy for the chemoprevention of certain cancers such as hepatocellular cancer. |
topic |
cytoguardin 5-methoxytryptophan cancer growth cancer metastasis cyclooxygenase-2 matrix metalloproteinase |
url |
https://www.mdpi.com/1422-0067/22/9/4490 |
work_keys_str_mv |
AT kennethkwu cytoguardinatryptophanmetaboliteagainstcancergrowthandmetastasis |
_version_ |
1721507349454127104 |